410
Participants
Start Date
April 1, 2025
Primary Completion Date
May 31, 2027
Study Completion Date
July 28, 2028
Pharmacogenetic and polygenic risk testing
The intervention involves: genetic testing; interpretation; and prior to and shortly following an upcoming appointment, communication to patients and providers about the patients' predicted statin efficacy and toxicity, genetic risk for CVD, and individualized recommended statin type/dose.
Active control
The control condition involves receipt of a report highlighting the risk of cardiovascular disease and benefits of statins (without genetic test
RECRUITING
Richard L. Roudebush VA Medical Center, Indianapolis, IN, Indianapolis
NOT_YET_RECRUITING
Durham VA Medical Center, Durham, NC, Durham
VA Office of Research and Development
FED